ID: PMRREP32722| Upcoming | Format: PDF, Excel, PPT* | Healthcare
According to the latest research by Persistence Market Research, the Mucosal Melanoma Treatment market is set to witness a growth of 12.6% during the forecast period. Demand for Mucosal Melanoma Treatment expects to witness stable recovery in the short-term, with a positive growth outlook in the long run. The growing improvement for the Mucosal Melanoma Treatment market industry will offer beneficial opportunities in near future.
Mucosal melanoma comparatively rare condition, demonstrating 8-15% of all malignant melanomas of the region and counting for less than 1% of all melanomas. Mucosal melanomas are very aggressive in behavior in contrast to other skin melanomas.
Major factors that account to the mucosal melanoma treatment market advancement include the rise in number of mucosal melanoma cases due to environmental factors and emergent awareness amongst people with regards to healthcare.
Other than the already mentioned factors, a worthwhile growth in the mucosal melanoma treatment demand is anticipated in the forecast due to the introduction of targeted therapy, which helps in reducing the side effects of treatment to the minimal and is also tremendously effective.
Approval of various drugs for mucosal melanoma treatment also proves to be a key driver for the progression of the demand focus. The market is seen to have shifted its focus to individualized therapy for every patient. It also includes an enormous injection of funds in the anti-melanoma treatment. These drivers are projected to create various new opportunities in the treatment market in the projection period.
There is a huge progress in the research about mucosal melanoma treatment where now, there is an understanding of the process of some DNA in the human body in the normal skin cells that can mutate to become melanoma cells. And with the identification of these gene mutations, there is a widened scope for targeted therapy in the mucosal melanoma treatment.
With the development of newer drugs like pembrolizumab (Keytruda), ipilimumab (Yervoy), the treatment for mucosal melanoma has taken a turn for good. These drugs are now used as mainstream treatment modalities for the therapy. These drugs induce therapeutic response at the disease site with increased efficacy and limited to no side effects.
Targeted drugs like the ones which work on cells with BARF gene changes, cells with changes in the C-KIT gene are the future of mucosal melanoma treatment demand.
Due to the high prevalence of melanoma in the region, advanced healthcare facilities, and increased research and development for mucosal melanoma drugs, North America has a dominant position in the melanoma treatment market. In addition, increased reimbursement policies and per capita income are expected to promote the development of the mucosal melanoma treatment market.
There is an increased awareness regarding various treatment options and the importance of healthcare amongst people which also proves to be a key driver for the market.
Universal biopharmaceutical company Alkermes plc (ALKS) recently, in 2021, received a fast-track designation from the FDA for Nemvaleukin for the treatment of mucous melanoma. This is proved to be an important milestone in the nemvaleukin development plan and emphasized the potential clinical utility of nemvaleukin in addressing the unmet medical needs of this difficult-to-treat tumor type.
Europe is the second largest market and is expected to grow significantly in the near future due to the increase in mucosal melanoma cases and the development of new therapies. In a report published in PubMed.gov, it was estimated that over 5204 new cases of melanoma are diagnosed every year, from which over 24.8% are mucosal melanomas.
Factors such as increased awareness, technological advancement and the high rate of patient adoption of this therapy have promoted the development of the European mucosal melanoma therapy market.
The mucosal melanoma treatment market has variety of key players like as follows:
Merck, on August 5th 2021, announced that the KEYNOTE716 phase 3 trial of Merck's anti-PD1 therapy, KEYTRUDA, has achieved relapse-free survival for its patients on adjuvant therapy. RFS is a high-risk stage II melanoma resected by surgery. In an interim analysis, the use of KEYTRUDA as monotherapy showed a statistically significant and clinically significant improvement in RFS compared to placebo as adjuvant treatment. No new safety signs were observed.
NOTE - All statements of fact, opinion, or analysis expressed in reports are those of the respective analysts. They do not necessarily reflect formal positions or views of the company.
By Treatment Type:
By Distribution Channels:
By Region:
The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain.
The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.
Delivery Timelines
For more information on this report and its delivery timelines please get in touch with our sales team.
